Nicholas Saraceno, Editor

Ryplazim is considered the first and only FDA-approved therapy specifically for the PLGD-1 indication.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, outlines the steps that pharma leaders should keep in mind to when combatting supply chain issues.

The CDMO's California facility welcomes new production suites, a revamp of its development labs, and more.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, details the types of regulatory pressures and factors surrounding rising R&D costs that will affect the pharmaceutical industry.

The media company utilized CMS data and worked with Medicare experts to pinpoint qualities that were highly valued to consumers.

The CDMO is investing $3.6 million toward boosting its advanced labeling, automated visual inspection, and fill-finish tech.

Could health system changes that improve patient access to medication have a positive effect on societal welfare?

The collaboration is centered on standardization and the promotion of safety data sharing when it comes to ground handling.

What are their satisfaction rates when it comes to telemedicine visits?

In the first part of this roundtable discussion, a panel of subject matter experts introduce themselves, while discussing why the pharma supply chain sees value in this technology and why its use has fluctuated over the past decade.

The collaboration ultimately benefits oncology patients, as life science companies will be able to access their cancer journey data more efficiently.

Investigators explore this potential association, including how it affects a child’s first two years of life.

The 50,000 square-foot plant is expected to augment the compounding and fulfillment experience for telehealth companies.

A cross-sectional study uses epidemiological patterns to investigate these disparities, while also predicting the potential shift of these patterns by 2050.

The 13,400 square-foot Belgium site will expand the company’s branded standardized bioprocessing, cryopreservation, and distribution solution for the cell therapy market, with a focus on leukapheresis starting materials.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, explains how the use of blockchain technology will become more prominent moving forward.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, offers his observations as to how stakeholders are building out their networks.

The conference returns to Lyon, France and promises a timely and relevant agenda that attendees will resonate with.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, describes how events such as the East and Gulf Coast port strikes have brought to light the differences between branded and generic pharmaceuticals.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, forecasts the future of the pharma cold chain regarding technological advancements and changes in market dynamics.

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, discusses the significant increase in demand for sustainable practices and outlines the company's initiatives in this area.

In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, explains why ultra-precise temperature control and customized logistics solutions are critical when it comes to biologics and personalized medicine.

In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, describes the progression of expectations when it comes to the sector, specifically as it relates to new drug development.

Albert Thigpen, co-founder, Talentwise Consulting, shares how today’s consumer is empowered to make their own decisions as it relates to consumer choices in general, while outlining how the concept can be applicable to the healthcare and pharma industry.

Albert Thigpen, co-founder, Talentwise Consulting, explains how the specialty pharmacy sector has evolved over the years.

Are SDOHs associated with Medicare, Medicaid, and private insurer spending?

Albert Thigpen, co-founder, Talentwise Consulting, discusses the valuable buckets pertaining to the PBM space.

With the design of the new 360,000 square-foot building, the CDMO’s goal is to continue to modernize its Laupheim site.

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Rob Sobie outlines the importance of supply chain transparency for the benefit of patients.